Never-before-seen 3D reconstructions of human liver tissue have been created at a cellular level. The details capture the spatial microstructure of multiple lobes of this multitasking organ. The reconstructions show how cirrhosis rearranges this intricate architecture and thereby alter the organ's biological activities. In addition, 3D liver maps with a high degree of cellular detail are critical to someday realizing the dream of bioprinting new organs for transplantation. 

New research from Memorial Sloan Kettering Cancer Center (MSK) investigates harnessing the power of ferroptosis to spread cell death; reports how an MSK artificial intelligence (AI) model could help improve patient safety; and uses AI to reveal country-specific drivers of global cancer outcomes.

St. Jude Children’s Research Hospital scientists found that hearing loss as a side effect of radiation therapy can increase the risk of cognitive decline. 

A Royal Orthopaedic Hospital NHS Foundation Trust (ROH) and Aston University collaboration has secured support to develop a minimally invasive anti-cancer and bone regenerative injectable paste, using the cancer-killing properties of gallium. 

The team has secured a place on the SPARK THE MIDLANDS programme which aims to provide academic support to advance healthcare research discoveries in the region. 

The team from the ROH includes Dr Lucas Souza, Professor Adrian Gardner, and Mr Jonathan Stevenson alongside Professor Richard Martin and Dr Eirini Theodosiou from Aston University. Together, they will use the SPARK programme to secure a route for the cancer-killing paste to be taken from the lab, into clinics and hospitals. If proved effective through clinical trials, the paste - a gallium-doped bioglass - could be used to treat patients with primary and metastatic bone cancer. 

Researchers have developed a new mRNA-based immunotherapy that effectively suppresses colorectal cancer in mice. Using lipid nanoparticles to deliver mRNA encoding anti-PD-L1 nanobodies, the treatment reduced tumor growth in both sporadic and colitis-associated colorectal cancer models. The quadruple nanobody format showed superior efficacy by prolonging therapeutic activity and enhancing anti-tumor immunity. This approach represents a promising alternative to conventional antibody therapies, particularly for cancers resistant to current immunotherapies.

Using machine learning, an electronic nose can “smell” early signs of ovarian cancer in the blood. The method is precise and, according to the LiU researchers behind the study, it could eventually be used to find many different cancers. The study is published in the scientific journal Advanced Intelligent Systems.